What Standard for Excessive Pricing in EU law? A Discussion of the Competition Appeal Tribunal’s Judgment in the Pfizer/Flynn v CMA Case Journal Artikel Jasper Hoekstra, Wolf Sauter European Pharmaceutical Law Review, Jahrgang 2 (2018), Ausgabe 4, Seite 215 - 221
Are You AI’S Favourite? EU Legal Implications of Biased AI Systems in Clinical Genetics and Genomics Anastasiya Kiseleva, Paul Quinn
A Case of Unforeseen Adverse Side-Effects? The Ireland/Northern Ireland Protocol and Medicines Regulation George Peretz, Xisca Borrás